Inventiva S.A.(IVA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IVA Inventiva S.A.

Trading 05-20 11:51:44 EDT

3.69

-0.11

-2.82%

High3.88	Low3.69	Vol3.27K
Open3.88	D1 Closing3.80	Amplitude4.92%
Mkt Cap193.40M	Tradable Cap57.66M	Total Shares52.37M
T/O12.48K	T/O Rate0.02%	Tradable Shares15.61M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"IVA","market":"US","secType":"STK","nameCN":"Inventiva S.A.","latestPrice":3.6929,"timestamp":1716219005590,"preClose":3.8,"halted":0,"volume":3272,"delay":0,"floatShares":15614393,"shares":52371073,"eps":-2.691362,"marketStatus":"Trading","change":-0.1071,"latestTime":"05-20 11:51:44 EDT","open":3.88,"high":3.88,"low":3.6929,"amount":12478.6665648,"amplitude":0.049237,"askPrice":3.85,"askSize":347,"bidPrice":3.54,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.691362,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1716235200000},"marketStatusCode":2,"adr":0,"adrRate":1,"listingDate":1594353600000,"exchange":"NASDAQ","adjPreClose":3.8,"preHourTrading":{"tag":"盘前","latestPrice":3.7,"preClose":3.8,"latestTime":"09:18 EDT","volume":40,"amount":148,"timestamp":1716211121072},"volumeRatio":1.375636},"requestUrl":"/m/hq/s/IVA/tweets","defaultTab":"tweets","newsList":[{"id":"2436991132","title":"Inventiva receives positive recommendation from DMC for late stage trial of NASH treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2436991132","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2436991132?lang=en_us&edition=fundamental","pubTime":"2024-05-17 20:58","pubTimestamp":1715950717,"startTime":"0","endTime":"0","summary":"Inventiva  announced the positive recommendation from the fourth scheduled meeting of the Data Monitoring Committee to continue the NATiV3 Phase III clinical trial evaluating lanifibranor in patients with MASH/NASH without modification to the current trial protocol. The Data Monitoring Committee recommended continuing the clinical trial without modification of the current protocol, based on the pre-planned review of safety data.  The recommendation was based on the unblinded review by the DMC of safety data from more than 900 patients randomized in the main and exploratory cohorts, including more than 360 and 80 patients that have been treated for more than 48 and 72 weeks, respectively. The patient who experienced the adverse event of increased liver test results, which was reported as a SUSAR, has been without clinical symptoms throughout the period of observation and has fully recovered. The DMC review confirms the good safety profile of lanifibranor. Source: Press Release","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4107908-inventiva-receives-positive-recommendation-from-dmc-for-late-stage-trial-of-nash-treatment","is_publish_highlight":false,"gpt_icon":0},{"id":"2436298771","title":"Inventiva’s Key Drug Trial Advances Positively","url":"https://stock-news.laohu8.com/highlight/detail?id=2436298771","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2436298771?lang=en_us&edition=fundamental","pubTime":"2024-05-17 05:29","pubTimestamp":1715894984,"startTime":"0","endTime":"0","summary":"Inventiva SA ADR (IVA) has released an update. Inventiva SA ADR has received a positive recommendation from the Data Monitoring Committee to procee...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/inventivas-key-drug-trial-advances-positively?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/inventivas-key-drug-trial-advances-positively?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2436193981","title":"Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH","url":"https://stock-news.laohu8.com/highlight/detail?id=2436193981","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2436193981?lang=en_us&edition=fundamental","pubTime":"2024-05-17 04:00","pubTimestamp":1715889600,"startTime":"0","endTime":"0","summary":"The Data Monitoring Committee recommended to continue the clinical trial without modification of the current protocol, based on the pre-planned review of safety data.The recommendation was based on the unblinded review by the DMC of safety data from more than 900 patients randomized in the main and exploratory cohorts, including more than 360 and 80 patients that have been treated for more than 48 and 72 weeks, respectively.Lanifibranor, Inventiva’s lead product candidate, is an orally-available small molecule that acts to induce anti-fibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body by activating all three peroxisome proliferator-activated receptor  isoforms, which are well-characterized nuclear receptor proteins that regulate gene expression. Lanifibranor is a PPAR agonist that is designed to target all three PPAR isoforms in a moderately potent manner, with a well-balanced activation of PPARα and PPARδ, and a partial activation of PPARγ. While the","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/XY_QbwknG0g_dMiiDPyLvw--~B/aD0xNzg7dz0zNzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/a1497e6e1366ecc45a71fef2ce2e7535","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/XY_QbwknG0g_dMiiDPyLvw--~B/aD0xNzg7dz0zNzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/a1497e6e1366ecc45a71fef2ce2e7535"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/inventiva-announces-positive-recommendation-fourth-200000143.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2435358564","title":"Inventiva SA ADR Announces Key General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2435358564","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2435358564?lang=en_us&edition=fundamental","pubTime":"2024-05-14 05:28","pubTimestamp":1715635694,"startTime":"0","endTime":"0","summary":"Inventiva SA ADR (IVA) has released an update. Inventiva SA ADR has announced its Ordinary and Extraordinary General Meeting for June 20, 2024, whe...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/inventiva-sa-adr-announces-key-general-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/inventiva-sa-adr-announces-key-general-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2435430219","title":"Why Is Inventiva's Stock Trading Higher on Monday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2435430219","media":"Benzinga","top":-1,"share":"https://ttm.financial/m/news/2435430219?lang=en_us&edition=fundamental","pubTime":"2024-05-14 04:08","pubTimestamp":1715630913,"startTime":"0","endTime":"0","summary":"InventivaSA announced thepublicationin the peer-reviewed scientific journalNature Communicationsof additional results from its NATIVE Phase 2b trial demonstrating the improvement of markers of cardiometabolic health in patients with MASH/NASHtreated withlanifibranor.Following lanifibranor treatment, the trial demonstrated significant improvement in patients with metabolic dysfunction-associated steatohepatitis / non-alcoholic steatohepatitis  with and without Type 2 Diabetes and with or without obesity of markers of cardiometabolic health.Lanifibranor treatment also led to lower fasting glucose to normal levels in 71% of patients with MASH/NASH and prediabetes treated with the 1200mg dose and 67% of patients treated with the 800mg dose versus 11% of patients on placebo.In addition, no patients treated with either dose oflanifibranorwith MASH/NASH and normoglycemia at baseline progressed to prediabetes at week 24, versus 26% of patients in the placebo arm.In addition, the increase in ad","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/WkyUP3QARV0Oyz3JgFdfTw--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/7329955d4f870a363984a5acc4558ae5","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/WkyUP3QARV0Oyz3JgFdfTw--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/7329955d4f870a363984a5acc4558ae5"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-inventivas-stock-trading-higher-200833005.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2435713326","title":"Inventiva’s Lanifibranor Shows Promise in MASH/NASH Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2435713326","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2435713326?lang=en_us&edition=fundamental","pubTime":"2024-05-13 19:28","pubTimestamp":1715599698,"startTime":"0","endTime":"0","summary":"Inventiva SA ADR (IVA) has released an update. Inventiva’s recent publication in Nature Communications reveals that its drug lanifibranor shows sig...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/inventivas-lanifibranor-shows-promise-in-mash-nash-treatment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/inventivas-lanifibranor-shows-promise-in-mash-nash-treatment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2435557312","title":"Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor","url":"https://stock-news.laohu8.com/highlight/detail?id=2435557312","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2435557312?lang=en_us&edition=fundamental","pubTime":"2024-05-13 14:30","pubTimestamp":1715581800,"startTime":"0","endTime":"0","summary":"Improvements were observed for insulin resistance , lipid metabolism , control of glycemia , systemic inflammation , hepatic steatosis and diastolic blood pressure.Among the patients who had prediabetes at study entry and were treated with lanifibranor, the majority had fasting glucose levels within the normal range at the end of treatment. No patient treated with lanifibranor with normal glucose levels at study entry progressed to prediabetes during treatment, unlike in the placebo arm.Adiponectin levels were increased by lanifibranor while they remained low and unchanged under placebo. Adiponectin increase was correlated with improvement of cardiometabolic health.A greater proportion of patients with MASH/NASH and high cardiovascular risk treated with either dose of lanifibranor saw their cardiovascular risk improved to intermediate or low risk compared to patients in the placebo arm.Importantly, lanifibranor treatment also led to lower fasting glucose to normal levels in 71% of pati","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/XY_QbwknG0g_dMiiDPyLvw--~B/aD0xNzg7dz0zNzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/a1497e6e1366ecc45a71fef2ce2e7535","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/XY_QbwknG0g_dMiiDPyLvw--~B/aD0xNzg7dz0zNzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/a1497e6e1366ecc45a71fef2ce2e7535"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/inventiva-announces-publication-nature-communications-063000203.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2428694687","title":"Hepion ends Phase 2 study for NASH drug due to cash restraints","url":"https://stock-news.laohu8.com/highlight/detail?id=2428694687","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2428694687?lang=en_us&edition=fundamental","pubTime":"2024-04-20 05:10","pubTimestamp":1713561014,"startTime":"0","endTime":"0","summary":"Hepion Pharmaceuticals (NASDAQ:HEPA) said it has begun winding down its ASCEND-NASH Phase 2 study for its drug rencofilstat as it continues to explore strategic alternatives for the company. “We are d","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/961746674/image_961746674.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/961746674/image_961746674.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4091671-hepion-ends-phase-2-study-for-nash-drug-due-to-cash-restraints","is_publish_highlight":false,"gpt_icon":0},{"id":"2428995505","title":"IntelePeer Integrates with Microsoft Azure OpenAI Service to Deliver AI Automation Solutions to Significantly Improve Customer Service","url":"https://stock-news.laohu8.com/highlight/detail?id=2428995505","media":"StreetInsider","top":-1,"share":"https://ttm.financial/m/news/2428995505?lang=en_us&edition=fundamental","pubTime":"2024-04-18 21:16","pubTimestamp":1713446160,"startTime":"0","endTime":"0","summary":"AI-powered Virtual Agents Create a Faster and Easier Customer Experience. IntelePeer, a leading AI-powered Communications Automation Platform provider, has integrated with Microsoft Azure OpenAI Service to embed OpenAI GPT into the company’s Communications Automation Platform and Intelligent Virtual Assistant , SmartAgent. With this integration, IntelePeer is delivering advanced solutions to fully automate customer interactions and improve operational efficiencies for businesses while creating a faster and easier customer experience.IntelePeer delivers vertical and domain-specific virtual agents for such industries as healthcare, insurance, utilities, retail, financial services, and transportation and logistics. The Company’s platform helps businesses quickly implement AI-powered omnichannel communications solutions that automates customer interactions. Since its inception, IntelePeer has automated over 500M customer interactions across voice, messaging and digital channels while lower","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=23083598","is_publish_highlight":false,"gpt_icon":0},{"id":"2426418781","title":"Maximus Launches Total Experience Management (TXM) Solution to Transform the Customer Experience of Federal Agencies","url":"https://stock-news.laohu8.com/highlight/detail?id=2426418781","media":"StreetInsider","top":-1,"share":"https://ttm.financial/m/news/2426418781?lang=en_us&edition=fundamental","pubTime":"2024-04-10 22:30","pubTimestamp":1712759400,"startTime":"0","endTime":"0","summary":"Maximus TXM is an industry-leading solution for federal agencies that improves CX by integrating emerging technologies and human-centered design principles. Maximus, a leading employer and provider of government services worldwide, today announced the launch of Maximus Total Experience Management , an integrated solution designed to help federal agencies deliver trusted information and government services simply, consistently, and securely. This new solution seamlessly integrates people, experience, data insights, and secure technologies into one digitally powered platform to reimagine government service delivery.Federal technology leaders can see a demonstration of Maximus TXM during the Salesforce World Tour event in Washington, D.C. The backbone of the Maximus solution is built on the powerful tools of Salesforce and other technology partners. “We appreciate our partnership with Maximus and integrating our latest solutions into Maximus TXM to of","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=23050301","is_publish_highlight":false,"gpt_icon":0},{"id":"2426190959","title":"Madrigal announces US launch of NASH/MASH drug Rezdiffra","url":"https://stock-news.laohu8.com/highlight/detail?id=2426190959","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2426190959?lang=en_us&edition=fundamental","pubTime":"2024-04-09 22:03","pubTimestamp":1712671428,"startTime":"0","endTime":"0","summary":"Madrigal Pharmaceuticals  said that its recently approved NASH/MASH drug Rezdiffra is now available in the US through a specialty pharmacy network.  Rezdiffra, also known as resmetirom, received accelerated approval by the FDA in March for the treatment of patients with non-alcoholic steatohepatitis, or NASH, and moderate-to-advanced liver fibrosis. NASH is also known as metabolic dysfunction-associated steatohepatitis, or MASH. Madrigal is currently conducting an outcomes study for Rezdiffra to support full FDA approval. Redizzfra is the first and only therapy to receive FDA approval for the treatment of NASH/MASH, according to the company. Other companies working on therapies for NASH/MASH include Eli Lilly , Novo Nordisk , GSK , Viking Therapeutics , Ascletis , Akero Therapeutics , 89bio , Sagimet Biosciences , Galectin Therapeutics , Gilead , Galmed , Ionis , Hepion , Terns Pharma , Inventiva  and Arrowhead .  More on Madrigal Pharmaceuticals  Madrigal: Accelerated Rezdiffra Approv","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1465361950/image_1465361950.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1465361950/image_1465361950.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4088257-madrigal-announces-us-launch-of-nashmash-drug-rezdiffra","is_publish_highlight":false,"gpt_icon":0},{"id":"2426110196","title":"Verint AI-Powered Platform Secures Top Honor for \"Best Use of AI\" at 2024 CX Awards","url":"https://stock-news.laohu8.com/highlight/detail?id=2426110196","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2426110196?lang=en_us&edition=fundamental","pubTime":"2024-04-09 20:30","pubTimestamp":1712665800,"startTime":"0","endTime":"0","summary":"Verint IVA Earns \"Highly Commended\" Recognition in \"Best Conversational Intelligence Solution\" Category. MELVILLE, N.Y., April 09, 2024----Verint , The Customer Engagement Company, announced today that its Open Platform was named winner in the \"Best Use of Artificial Intelligence \" category at the 2024 CX Awards. Verint Intelligent Virtual Assistant  was also recognized with a \"highly commended\" distinction in the \"Best Conversational Intelligence Solution\" category. These accolades underscore Verint's position as a market leader in the customer experience  automation category.The Verint Open Platform makes it possible to modernize a brand’s contact center operations with AI-powered bots without requiring a risky or disruptive rip and replace of the entire ecosystem. An integral component of the Verint Open Platform, Verint IVA, was also awarded the \"highly commended\" designation in the \"Best Conversational Intelligence Solution\" category. Powered by the Verint Data Hub and Verint Da V","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/fjMt4JOPEKDZLFD00zz07A--~B/aD0zOTA7dz0xNTAxO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/d973706066ad1e77ea65692b51e3bd42","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/fjMt4JOPEKDZLFD00zz07A--~B/aD0zOTA7dz0xNTAxO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/d973706066ad1e77ea65692b51e3bd42"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/verint-ai-powered-platform-secures-123000601.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2426468156","title":"Inventiva (NASDAQ:IVA) Price Target Increased to $20.00 by Analysts at Canaccord Genuity Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2426468156","media":"Defense World","top":-1,"share":"https://ttm.financial/m/news/2426468156?lang=en_us&edition=fundamental","pubTime":"2024-04-09 16:03","pubTimestamp":1712649819,"startTime":"0","endTime":"0","summary":"Inventiva (NASDAQ:IVA) Price Target Increased to $20.00 by Analysts at Canaccord Genuity Group","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"redbox_crawler","url":"https://news.google.com/rss/articles/CBMihwFodHRwczovL3d3dy5kZWZlbnNld29ybGQubmV0LzIwMjQvMDQvMDkvaW52ZW50aXZhLW5hc2RhcWl2YS1wcmljZS10YXJnZXQtaW5jcmVhc2VkLXRvLTIwLTAwLWJ5LWFuYWx5c3RzLWF0LWNhbmFjY29yZC1nZW51aXR5LWdyb3VwLmh0bWzSAQA?oc=5","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://news.google.com/rss/articles/CBMihwFodHRwczovL3d3dy5kZWZlbnNld29ybGQubmV0LzIwMjQvMDQvMDkvaW52ZW50aXZhLW5hc2RhcWl2YS1wcmljZS10YXJnZXQtaW5jcmVhc2VkLXRvLTIwLTAwLWJ5LWFuYWx5c3RzLWF0LWNhbmFjY29yZC1nZW51aXR5LWdyb3VwLmh0bWzSAQA?oc=5","is_publish_highlight":false,"gpt_icon":0},{"id":"2425735998","title":"Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), CervoMed (CRVO) and Teladoc (TDOC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2425735998","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2425735998?lang=en_us&edition=fundamental","pubTime":"2024-04-08 19:30","pubTimestamp":1712575811,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Inventiva (IVA – Research Report), CervoMed (CRVO – ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-inventiva-iva-cervomed-crvo-and-teladoc-tdoc?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-inventiva-iva-cervomed-crvo-and-teladoc-tdoc?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2424825353","title":"Inventiva’s Latest Move: Issuing Royalty Certificates That Could Dilute Lanifibranor Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2424825353","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2424825353?lang=en_us&edition=fundamental","pubTime":"2024-04-04 14:00","pubTimestamp":1712210429,"startTime":"0","endTime":"0","summary":"Inventiva SA ADR (IVA) has disclosed a new risk, in the Share Price & Shareholder Rights category. Inventiva SA ADR’s decision on August 30, 2023, ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/inventivas-latest-move-issuing-royalty-certificates-that-could-dilute-lanifibranor-earnings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/inventivas-latest-move-issuing-royalty-certificates-that-could-dilute-lanifibranor-earnings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2424995872","title":"Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F","url":"https://stock-news.laohu8.com/highlight/detail?id=2424995872","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2424995872?lang=en_us&edition=fundamental","pubTime":"2024-04-04 04:00","pubTimestamp":1712174400,"startTime":"0","endTime":"0","summary":"Daix , Long Island City , April 3, 2024 – Inventiva  , a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis , also known as non-alcoholic steatohepatitis , and other diseases with significant unmet medical needs, today announced that it had filed its 2023 Universal Registration Document for the year ended December 31, 2023, including the management report and the annual financial report, with the French “Autorité des Marchés Financiers”  and its 2023 Annual Report on Form 20-F for the year ended December 31, 2023 with the U.S. Securities and Exchange Commission .Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris  and on the Nasdaq Global Market in","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/XY_QbwknG0g_dMiiDPyLvw--~B/aD0xNzg7dz0zNzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/a1497e6e1366ecc45a71fef2ce2e7535","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/XY_QbwknG0g_dMiiDPyLvw--~B/aD0xNzg7dz0zNzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/a1497e6e1366ecc45a71fef2ce2e7535"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/inventiva-announces-filing-2023-universal-200000488.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2424273724","title":"Inventiva S.A. (NASDAQ:IVA) Q4 2023 Earnings Call Transcript","url":"https://stock-news.laohu8.com/highlight/detail?id=2424273724","media":"Insider Monkey","top":-1,"share":"https://ttm.financial/m/news/2424273724?lang=en_us&edition=fundamental","pubTime":"2024-04-02 02:17","pubTimestamp":1711995422,"startTime":"0","endTime":"0","summary":"Inventiva S.A.  Q4 2023 Earnings Call Transcript March 28, 2024 Inventiva S.A. isn't one of the 30 most popular stocks among hedge funds at the end of the third quarter (. Operator: Good day and thank you for standing by. Welcome to the Inventiva Annual Results 2023 conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. [Operator Instructions]. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today. Frederic Cren, please go ahead.Making lani the first drug candidate to our knowledge to receive such designation from both the FDA and the NMPA for the treatment of MASH/NASH. We also published the results, a positive result of a study conducted by Professor Cusi from the University of Florida in 2023. The study met its primary endpoint which demonstrated the reduction of [Indiscernible] patients with MAFLD/ NAFLD and Typ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/0XDqiFcfoetrCuQSqjo2vg--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/0e2f2f879338346cb3f7593762d4e58e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/0XDqiFcfoetrCuQSqjo2vg--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/0e2f2f879338346cb3f7593762d4e58e"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/inventiva-nasdaq-iva-q4-2023-181702380.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422811855","title":"Analysts Are Bullish on Top Healthcare Stocks: Inventiva (IVA), Palisade Bio (PALI)","url":"https://stock-news.laohu8.com/highlight/detail?id=2422811855","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2422811855?lang=en_us&edition=fundamental","pubTime":"2024-03-28 22:10","pubTimestamp":1711635031,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Inventiva (IVA – Research Report) and Palisade Bio (...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-inventiva-iva-palisade-bio-pali?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-inventiva-iva-palisade-bio-pali?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2422169898","title":"Alight’s Latest Release of Alight Worklife® to Unlock Value for Organizations and Their People","url":"https://stock-news.laohu8.com/highlight/detail?id=2422169898","media":"Business Wire","top":-1,"share":"https://ttm.financial/m/news/2422169898?lang=en_us&edition=fundamental","pubTime":"2024-03-28 19:00","pubTimestamp":1711623600,"startTime":"0","endTime":"0","summary":"First release of 2024 offers AI-driven workforce support, extensive benefits management and holistic financial and wellbeing features to enhance the employee experience and help generate higher ROI for employers. LINCOLNSHIRE, Ill., March 28, 2024----Alight, Inc. , a leading cloud-based human capital and technology services provider, today announced the first major release of Alight Worklife for 2024.The release introduces AI-powered workforce support, comprehensive benefits management, and holistic financial and wellbeing capabilities to improve the employee experience and help generate increased ROI for employers.\"The Alight Worklife platform offers comprehensive benefits and wellbeing solutions, including benefits administration and opportunities for cost reduction in healthcare spend, leading to financial security for employees and elevating the employee experience,\" said Josh Welch, EVP of product management at Alight. \"With this release, employers will be better positioned to max","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/u9Wt5QOCyrOsRxVSzblWUw--~B/aD0yNzU7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/e583cf66deecacefcac0ea63ed2940f4","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/u9Wt5QOCyrOsRxVSzblWUw--~B/aD0yNzU7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/e583cf66deecacefcac0ea63ed2940f4"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alight-latest-release-alight-worklife-110000901.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422131892","title":"Inventiva announces the nomination of Andre Turenne as Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2422131892","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2422131892?lang=en_us&edition=fundamental","pubTime":"2024-03-28 15:00","pubTimestamp":1711609200,"startTime":"0","endTime":"0","summary":"Daix , Long Island City , March 28, 2024 – Inventiva  , a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis , also known as non-alcoholic steatohepatitis  and other diseases with significant unmet medical needs, today announced the nomination of Andre Turenne to its Board of Directors. Mr. Turenne’s appointment will be submitted to the shareholders for ratification at the next general shareholder meeting.Inventiva’s lead product candidate, lanifibranor, is currently in a pivotal Phase III clinical trial, NATiV3, for the treatment of adult patients with MASH/NASH, a common and progressive chronic liver disease for which there are currently no approve","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/XY_QbwknG0g_dMiiDPyLvw--~B/aD0xNzg7dz0zNzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/a1497e6e1366ecc45a71fef2ce2e7535","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/XY_QbwknG0g_dMiiDPyLvw--~B/aD0xNzg7dz0zNzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/a1497e6e1366ecc45a71fef2ce2e7535"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/inventiva-announces-nomination-andre-turenne-070000994.html","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://inventivapharma.com","stockEarnings":[{"period":"1week","weight":0.1225},{"period":"1month","weight":0.1783},{"period":"3month","weight":0.1463},{"period":"6month","weight":-0.037},{"period":"1year","weight":0.4},{"period":"ytd","weight":-0.1599}],"compareEarnings":[{"period":"1week","weight":0.0165},{"period":"1month","weight":0.0577},{"period":"3month","weight":0.0599},{"period":"6month","weight":0.1745},{"period":"1year","weight":0.2629},{"period":"ytd","weight":0.1139}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of mucopolysaccharidoses type VI disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.033773},{"month":2,"riseRate":0.5,"avgChangeRate":-0.02424},{"month":3,"riseRate":0,"avgChangeRate":-0.114231},{"month":4,"riseRate":0,"avgChangeRate":-0.166714},{"month":5,"riseRate":0.75,"avgChangeRate":0.165828},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.116382},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.052},{"month":8,"riseRate":0.25,"avgChangeRate":0.014638},{"month":9,"riseRate":0.5,"avgChangeRate":0.005555},{"month":10,"riseRate":0.75,"avgChangeRate":0.065387},{"month":11,"riseRate":0.25,"avgChangeRate":-0.033954},{"month":12,"riseRate":1,"avgChangeRate":0.075845}],"exchange":"NASDAQ","name":"Inventiva S.A.","nameEN":"Inventiva S.A."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Inventiva S.A.(IVA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Inventiva S.A.(IVA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Inventiva S.A.,IVA,Inventiva S.A.股票,Inventiva S.A.股票老虎,Inventiva S.A.股票老虎国际,Inventiva S.A.行情,Inventiva S.A.股票行情,Inventiva S.A.股价,Inventiva S.A.股市,Inventiva S.A.股票价格,Inventiva S.A.股票交易,Inventiva S.A.股票购买,Inventiva S.A.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Inventiva S.A.(IVA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Inventiva S.A.(IVA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction